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Blocking LINGO-1 in vivo reduces degeneration
and enhances regeneration of the optic nerve
Melissa M Gresle, Yaou Liu, Trevor J Kilpatrick, Dennis Kemper, Qi-Zhu Wu, Bing Hu,
Qing-Ling Fu, Kwok-Fai So, Guoqing Sheng, Guanrong Huang, Blake Pepinsky,
Helmut Butzkueven and Sha Mi
Abstract
Background: Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to
test the efficacy of anti-LINGO-1 antibodies in acute optic neuritis and relapsing forms of multiple
sclerosis, respectively. Across a range of experimental models, LINGO-1 has been found to inhibit
neuron and oligodendrocyte survival, axon regeneration, and (re)myelination. The therapeutic effects of
anti-LINGO-1 antibodies on optic nerve axonal loss and regeneration have not yet been investigated.
Objective: In this series of studies we investigate if LINGO-1 antibodies can prevent acute inflamma-
tory axonal loss, and promote axonal regeneration after injury in rodent optic nerves.
Methods: The effects of anti-LINGO-1 antibody on optic nerve axonal damage were assessed using
rodent myelin oligodendrocyte glycoprotein experimental autoimmune encephalomyelitis (EAE), and its
effects on axonal regeneration were assessed in optic nerve crush injury models.
Results: In the optic nerve, anti-LINGO-1 antibody therapy was associated with improved optic nerve
parallel diffusivity measures on MRI in mice with EAE and reduced axonal loss in rat EAE. Both anti-
LINGO-1 antibody therapy and the genetic deletion of LINGO-1 reduced nerve crush-induced axonal
degeneration and enhanced axonal regeneration.
Conclusion: These data demonstrate that LINGO-1 blockade is associated with axonal protection and
regeneration in the injured optic nerve.
Keywords: Optic neuritis, optic nerve degeneration and regeneration, axons and retinal ganglion cells,
LINGO-1, anti-LINGO-1 antibody, multiple sclerosis
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Introduction
Axonal degeneration and neuronal loss often lead to
progressive functional impairment and worsening
disability in central nervous system (CNS) disorders
such as multiple sclerosis (MS), Parkinson’s disease,
and glaucoma.18 Neuroprotective agents could offer
a new therapeutic approach to complement the cur-
rent standards of care by reducing the neuronal
degeneration rate and/or preserving or restoring
CNS neuronal function.8 Previous efforts at develop-
ing CNS regeneration therapeutics focused on neu-
rotrophins and growth factors and were not clinically
successful because of their lack of tissue specificity
and attendant off-target tissue toxicity.8
Leucine-rich repeat and immunoglobulin-like
domain-containing Nogo receptor-interacting
protein 1 (LINGO-1) represents an attractive
target for therapeutic intervention across a range
of neurodegenerative CNS disorders.8 LINGO-1 is
a potent negative regulator of oligodendrocyte dif-
ferentiation, neuronal and axonal survival, and
axonal regeneration.810 Unlike other known nega-
tive myelination regulators, such as g-secretase11 or
chemokine receptor CXCR2,12 LINGO-1 is select-
ively expressed in the CNS.9,10,13,14
LINGO-1 expression is up-regulated in animal
models of spinal cord injury, MS, Parkinson’s dis-
ease, and glaucoma.8 In human postmortem studies,
LINGO-1 expression is increased in Parkinson’s dis-
ease and MS brain tissue.8 In vitro, attenuation of
LINGO-1 expression or function enhances oligo-
dendrocyte differentiation, myelination, neuronal
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survival, and axonal regeneration, as well as
functional recovery in animal models of CNS
demyelination.8,15 Blocking or ablating LINGO-1
function in experimental autoimmune encephalomy-
elitis (EAE) using LINGO-1-null mice or an anti-
LINGO-1 neutralizing antibody facilitates remyeli-
nation.15 In murine toxin-induced Parkinson’s dis-
ease models, dopamine neuron survival was
increased and behavioral abnormalities reduced in
LINGO-1-null versus wild-type mice,16 and in a
glaucoma disease model, LINGO-1 antagonism pro-
moted retinal ganglion cell (RGC) survival.8
Optic neuritis (ON) occurs in MS17 and is character-
ized by acute inflammatory optic nerve demyelin-
ation, resulting in RGC loss, axonal degeneration,
and, potentially, permanent visual impairment.1719
Currently, no neuroprotective or neuroregenerative
therapies are approved for treating ON associated
with MS. Here we assessed whether pharmacologic
antagonism of LINGO-1 function with monoclonal
blocking antibodies had beneficial effects on either
axon protection or regeneration in the optic nerve
in vivo. The experiments used rodent EAE models
of acute inflammatory axonal injury, and optic nerve
crush injury models, to assess effects on axonal
degeneration and axonal regeneration, respectively.
Materials and methods
Animal care
All animal handling and surgical procedures were
approved by the Howard Florey Institute Animal
Ethics Committee or Biogen’s Animal Care and
Use Committee.
Monoclonal antibody (mAb) preparations
Three different anti-LINGO-1 mAbs were used in
the mouse EAE (3B5), rat EAE (BIIB033), and rat
optic nerve crush studies (1A7); all were supplied by
Biogen (Cambridge, MA, USA). As these studies par-
alleled the clinical development of anti-LINGO-1
antibodies, we were unable to access the same
antibody preparations for all experiments. These
mAbs target different LINGO-1 epitopes, but likely
have similar blood-brain barrier penetration
(0.1%).8 Human, rat, and mouse LINGO-1 share
99.5% identity.8 BIIB033 and 3B5 bind human and
mouse LINGO-1 with the same affinity (unpublished
data). 1A7 was administered by local and intravitreal
delivery in these experiments because of its 100-fold
lower affinity for rat LINGO-1 than BIIB033 and 3B5
(unpublished data); BIIB033 and 3B5 were given
intraperitoneally (IP).
Assessing the effects of LINGO-1 antibody therapy
on optic nerve axonal loss in murine EAE by diffu-
sion-weighted imaging and histology
Optic nerve parallel and perpendicular diffusivity
detected by diffusion magnetic resonance imaging
(MRI) have been validated as measures of axonal
degeneration and demyelination, respectively.20,21
We previously demonstrated that C57BL/6 mouse
myelin oligodendrocyte glycoprotein peptide amino
acid 35 to 55 (MOG3555) EAE is associated with
reduced optic nerve parallel diffusivity, with no
change in perpendicular diffusivity.22 Importantly,
we also confirmed that parallel diffusivity reduction
was highly correlated with optic nerve axonal atro-
phy measured by histology, and that gross selective
demyelination or oligodendrocyte loss in the optic
nerve are not features of the pathology of this
model at paraplegia onset. In the present study we
used C57BL/6 MOG-EAE to measure the efficacy of
anti-LINGO-1 antibody therapy on acute inflamma-
tory optic nerve axonal injury in the absence of
selective demyelination and oligodendrocyte loss.
EAE was induced in 8- to 12-week-old C57BL/6
male and female mice, using MOG3555 (95%
purity; Auspep Pty Ltd, Victoria, Australia) emulsi-
fied in complete Freund’s adjuvant containing
Mycobacterium tuberculosis H37Ra 4 mg/ml
(Difco, Detroit, MI, USA), followed by intravenous
injection of pertussis toxin 300 ng in phosphate-buf-
fered saline (PBS) immediately afterwards and 3
days later.23,24
EAE severity was assessed daily using a standar-
dized seven-step paraplegia scale, where 0 signifies
no disease and 7 signifies death.2527 Two separate
cohorts of 14 mice each (n ¼ 28 total) received, in a
blinded fashion, 10 mg/kg IP anti-LINGO-1 mouse
mAb 3B5 (n ¼ 7) or a control mAb IP (n ¼ 7).
Another five mice were included as healthy controls
for histological studies. Mice were treated four
times, once every 3 days, starting on day 6 post
EAE induction and before onset of symptoms.
Optic nerve diffusion tensor MRI scans were con-
ducted under anesthesia on control-exposed and
anti-LINGO-1-exposed mice at peak EAE disease
severity on day 16 or 17 post induction. Mice were
anesthetized with 2.5% isoflurane using an MR-com-
patible head holder and nose cone over the snout,
and anesthesia maintained with 0.52.0% isoflur-
ane.22 Animals euthanized because of disease sever-
ity before day 16 were not analyzed. The optic nerve
regions of interest (ROI) comprised 10 voxels in the
center of the optic nerves at the prechiasmal level.
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The optic nerve was imaged using a diffusion-
weighted sequence with a spin-echo acquisition on
a Bruker 4.7T MRI system (Bruker Corporation,
Billerica, MA, USA). MRI images were acquired
with the following parameters: repetition time of
1 s, echo time of 30 ms,  of 10 ms, number of exci-
tations of eight, slice thickness 0.5 mm, field of view
2 2 cm2, and data matrix 256 128. We employed
b-values of 0 s/mm2 (nondiffusion-weighted image)
and 700 s/mm2 for one parallel and one perpendicular
diffusion-sensitizing gradient directions.22
Immediately following MRI, mice were euthanized
(100 mg/kg IP pentobarbital), transcardially perfused
with 0.1 M PBS and 4% paraformaldehyde (PFA),
and the optic nerves were removed. Optic nerves
were postfixed in 4% PFA, 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer, and processed for
high-resolution light microscopy as previously
described.28 Images were taken from 0.5-mm thick
methylene blue stained whole prechiasmal cross-sec-
tional optic nerve sections at 10 and 100 magni-
fication and merged using Photoshop CS3e (Adobe
Systems Inc, San Jose, CA, USA). Five prechiasmal
optic nerve ROIs were chosen for analysis, four per-
ipheral and one central, each measuring 3600 mm2.
Analysis was conducted using Image-Pro Plus
(Media Cybernetics Inc, Rockville, MD, USA) to
assess axonal number, axonal area, and axoplasmal
area of each identified axon, for each ROI as previ-
ously described.28 The peripheral and central nerve
areas were assessed separately for each nerve.
Assessing the effects of LINGO-1-antibody therapy
on optic nerve axonal loss in rat EAE
To induce EAE, 8- to 10-week-old female Brown
Norway rats were anesthetized by isoflurane inhal-
ation, and injected intradermally at the tail base with
200 ml of inoculum, containing 100 mg rMOG1125 in
saline emulsified (1:1) with complete Freund’s adju-
vant containing 400 mg heat-inactivated
Mycobacterium tuberculosis. After the onset of clin-
ical symptoms (1516 days after induction), rats
were exposed to 30 mg/kg/day methylprednisolone
in 5 ml/kg of saline solution (0.9% sodium chloride)
or saline solution alone (vehicle) intravenously for
3 consecutive days. Beginning on the second day,
rats were given three weekly IP injections of either
6 mg/kg of anti-LINGO-1 mAb BIIB033 or control
mAb. Thus, there were four different groups: (a)
vehicle þ control mAb; (b) methylprednisolone þ
control mAb; (c) vehicle þ mAb BIIB033; or (d)
methylprednisolone þ mAb BIIB033.
One week after the last mAb dose, animals were
euthanized and perfused with 4% PFA in PBS.
Twenty-micrometer thick frozen sections of optic
nerves were stained with anti-bIII tubulin antibody
(BioLegend Inc, San Diego, CA, USA) and Alexa
Fluor 488 goat anti-mouse antibody (Life
Technologies, Carlsbad, CA, USA (now
ThermoFisher Scientific)) and 4’,6- diamidino-2-
phenylindole (DAPI) and visualized by fluorescence
microscopy at 40 magnification. For axonal quan-
tification, three consecutive sections per optic nerve
per animal were analyzed, and three to five animals
were counted per group.
Measuring axonal degeneration/regeneration fol-
lowing optic nerve crush injury
We used the optic nerve crush model to investigate
the effects of anti-LINGO-1 antibody on axonal
regeneration in the optic nerve.
Rat optic nerve crush surgery was performed in adult
female Sprague Dawley rats as previously
described.29 Immediately after optic nerve crush,
anti-LINGO-1 mAb 1A7 (n ¼ 4) or vehicle
(n ¼ 8) was injected into either the vitreous chamber
of the eye or locally at the crush site. Fluorescein
isothiocyanate-conjugated cholera subunit toxin B
(FITC-CTB) was injected into the eye to anterograde
label intact RGC axons. Fluoro-GoldTM
(Fluorochrome, LLC, Denver, CO, USA) was
applied at the crush site to retrograde label RGC
somata.
Animals were sacrificed after 2 weeks and tissue
processed for visualization and quantification. For
expression of LINGO-1, 16-mm thick frozen sections
of retina were incubated with mouse anti-LINGO-1
(1:200; Biogen) and visualized using fluorescent
goat anti-mouse antibody (Alexa Fluor 568; Life
Technologies). To evaluate optic nerve axonal
morphology after crush, frozen sections of the
optic nerve were processed to visualize FITC-CTB-
labeled axons, and the number of axons that had
regrown beyond the crush site was measured.
To confirm that LINGO-1 inhibition is associated
with optic nerve axonal regeneration, optic nerve
crush surgery was also conducted in 8- to 9-week-
old LINGO-1-null mice (n ¼ 5) and C57BL6/J mice
(n ¼ 4) using Dumont #5SF forceps (Fine Science
Tools, Foster City, CA, USA) for 2 s approximately
1 mm behind the optic disc, as previously
described.30
Gresle et al.
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To evaluate regenerated axons, intravitreous injec-
tion of Alexa Fluor 488-conjugated CTB (2 mg/ml;
Life Technologies) was performed 2 days before the
experimental endpoint. Four weeks after surgery,
animals were perfused with 4% PFA. Optic nerves
were dissected out and postfixed in the same fixative
overnight at 4C. Tissues were cryoprotected in 30%
sucrose overnight at 4C, and embedded in optimal
cutting temperature compound (Fisher Scientific,
Pittsburgh, PA, USA). Optic nerves were cut longi-
tudinally (8 mm) and imaged with a 20 objective
using a slide scanner (VS120 (Olympus Life
Sciences, Waltham, MA, USA)).
The numbers of CTB-labeled axons that crossed
different distances from the crush site per section
were determined in four sections per mouse to
quantify regenerating RGC axons in crushed optic
nerves.
Statistics
All data were analyzed using descriptive statistics. In
mouse EAE, mortality and paraplegia curves are
shown as percentage of total animals exposed, as
analyzed using the log-rank sum test (GraphPad
Prism version 4.01, La Jolla, CA, USA). All other
comparisons between treatment groups were
assessed using one-way analysis of variance or
unpaired t tests. Data are available from the authors.
Results
A summary of the main findings for each experiment
can be found in Table 1.
LINGO-1 antagonism reduces morbidity/mortality
and improves optic nerve MRI parallel diffusivity in
MOG-EAE mice
Mice that received control antibody developed acute
monophasic EAE with ascending paralysis starting
910 days after immunization (Figure 1(a)). The
proportion of mice reaching complete hindlimb par-
alysis (i.e. grade 3.0 disease severity)27 in the control
antibody-exposed group (seven of 14 mice) was
higher than in the anti-LINGO-1 mAb 3B5-exposed
group (four of 14 mice; p ¼ 0.002). Moreover, there
was no EAE mortality in mAb 3B5-exposed mice,
whereas five of 14 mice exposed to control had to be
euthanized because of EAE severity (p ¼ 0.007;
Figure 1(b)).
Diffusion-weighted MRI showed significantly higher
apparent diffusion coefficient values parallel to the
long axis (longitudinal, axial, or parallel diffusivity
or I) in mAb 3B5-exposed mice (mean SD,
1400 27 mm2/s) versus control-exposed mice Ta
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(1183 36 mm2/s; p< 0.01; Figure 2). In contrast,
there was no difference in apparent diffusion coeffi-
cient values perpendicular to the optic nerve long
axis (radial or perpendicular diffusivity or o;
415 19 mm2/s in mAb 3B5-exposed versus
403 25 mm2/s in control mice).
Histological analyses conducted immediately after
MRI found no differences in total cross-sectional
optic nerve area, number of axons in the central or
peripheral ROI, or individual axonal area (a measure
of axonal health) in the peripheral optic nerve ROI in
control mice versus mAb 3B5-exposed mice
(Table 2, Figure 3). Importantly, the individual
axonal area of the central ROI in the optic nerve
trended 13% lower in control-treated mice relative
to anti-LINGO-1-treated mice (p ¼ 0.07, Table 2).
LINGO-1 antagonism protected the optic nerve from
axonal degeneration in rat MOG-EAE
Axonal loss was detected in sections of rat optic
nerves from the control group (vehicle þ control
antibody) by quantitating anti-bIII tubulin-stained
axons (Figure 4). Inflammatory infiltration was
observed in these areas by DAPI staining, confirm-
ing the presence of ON. No axonal protection
occurred with daily exposure for 3 days with high-
dose intravenous methylprednisolone. In contrast,
anti-LINGO-1 mAb BIIB033 exposure alone
(vehicle þ BIIB033) was associated with a five-
fold higher axonal number than exposure to control,
indicating that mAb BIIB033 exposure reduced
axonal loss. Rats exposed to a combination of
methylprednisolone and mAb BIIB033 showed an
eight-fold increase in axonal number versus con-
trol-exposed rats, indicating that high-dose cortico-
steroids did not interfere with the axonal protective
effects of mAb BIIB033. There was no significant
difference in axonal number between the group
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Figure 1. LINGO-1 blockade reduced morbidity and mortality of myelin oligodendrocyte glycoprotein
experimental autoimmune encephalomyelitis (MOG-EAE) mice. (a) The percentage of MOG-EAE mice
reaching complete hindlimb paralysis (grade 3 disease severity) exposed to anti-LINGO-1 monoclonal anti-
body (mAb) 3B5 or control antibody (ctrl Ab). (b) The percentage survival of MOG-EAE mice exposed to
mAb 3B5 or ctrl Ab. Data shown as mean  standard deviation (SD). Day 16 p values were determined using
a log-rank test. LINGO-1: leucine-rich repeat and immunoglobulin-like domain-containing Nogo receptor-
interacting protein 1.
Figure 2. LINGO-1 blockade protected optic nerve
axonal integrity of myelin oligodendrocyte glyco-
protein experimental autoimmune encephalomyelitis
(MOG-EAE) mice. Analysis of optic nerve axonal
integrity by diffusion-weighted imaging in mouse
MOG-EAE exposed to anti-LINGO-1 monoclonal
antibody (mAb) 3B5 or control antibody (ctrl Ab).
Imaging was performed on day 16 or 17 after
induction of EAE. Data shown as mean  SD.
p value was determined using a t test. LINGO-1:
leucine-rich repeat and immunoglobulin-like
domain-containing Nogo receptor-interacting pro-
tein 1.
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exposed to mAb BIIB033 alone and the group
exposed to mAb BIIB033 þ methylprednisolone.
LINGO-1 antagonism led to increased axonal
regeneration following optic nerve crush
Optic nerve crush experiments were used to assess
the effects of LINGO-1 blockade on optic nerve
axon regeneration in rats. Immunohistochemical
staining showed strong LINGO-1 expression in
RGCs (Figure 5). In control rats, FITC-CTB labeling
showed dramatic axonal degeneration and collapse
of optic nerve fibers at the lesion site. In contrast,
axonal degeneration was decreased in mAb 1A7-
exposed rats, as evident from labeled axons in
close proximity to the lesion site (Figure 6(a)).
Additionally, mAb 1A7-exposed rats showed
enhanced axonal outgrowth compared with control-
exposed rats (Figure 6(b)). Quantification of regen-
erating axons showed that blocking LINGO-1 by
local and, to a lesser extent, intravitreal injection of
mAb 1A7 induced increased axonal regeneration
relative to control exposure (Figure 6(c)).
LINGO-1-null mice were used to confirm that
absence of LINGO-1 also enhanced optic nerve
axonal regeneration. As shown in Figure 7, there
was a two-fold increase in CTB-labeled regenerating
axons in LINGO-1-null mice compared with wild-
type mice at 100, 250, and 500 mm distal to the crush
site.
Discussion
We have shown that blocking LINGO-1 function
protects against optic nerve axonal degeneration in
EAE, and promotes axonal regeneration following
optic nerve crush injury.
Using the murine MOG-EAE model, we show that
LINGO-1 blockade not only reduces disease severity
and mortality, but also promotes improvements in
optic nerve parallel diffusivity as measured by
MRI. In previous studies, we confirmed that parallel
diffusivity reductions in the mouse optic nerve fol-
lowing MOG-EAE likely reflect axonal degener-
ation,22,31 supported by histological evidence of
reductions in axon numbers and area in semi-thin
sections.22 We also demonstrated that changes in
perpendicular diffusivity and selective demyelin-
ation are not features of this model. Collectively,
our findings suggest that in the absence of gross
selective demyelination, anti-LINGO-1 antibody
therapy is likely to reduce axonal degeneration in
the optic nerves of EAE mice. Importantly, although
edema associated with inflammatory cell infiltration
is known to affect MRI diffusivity measures, previ-
ous studies confirm this is not detectable in EAE
mouse optic nerves despite evidence of marked
inflammatory cell infiltration.22 Thus, it is unlikely
that changes in inflammatory cell numbers are con-
tributing to increased parallel diffusivity measures in
the optic nerves of anti-LINGO-1-treated mice.
In this study we were unable to demonstrate conclu-
sively by histology that axon pathology was
decreased with anti-LINGO-1 therapy. We do
report a strong trend to preserved individual axoplas-
mal area within the central optic nerve, in support of
the MRI findings. These observations could be partly
explained by the need to euthanize 35% of mice in
the control group because of EAE severity, and their
exclusion from histological analyses. Alternatively,
the time point at which histology was performed may
have been too early in the disease course to see an
effect on axon numbers (as a strong trend toward
Table 2. Quantitative histology (mean  SE) of the optic nerve in MOG-EAE mice, 1617 days after EAE induction.
Histological analysis Healthy Control antibody Anti-LINGO-1
mAb 3B5
p valuea
Optic nerve area (mm2) 85,600 200 85,600 2900 85,000 3800 0.77
Average central axon area (mm2) 0.46 0.01 0.26 0.01 0.30 0.01 0.07
Peripheral axon area (mm2) 0.57 0.08 0.32 0.01 0.33 0.01 0.80
Total central axon count 19,500 2500 18,300 800 17,400 1300 0.56
Total peripheral axon count 29,500 7400 21,900 1000 22,100 1400 0.90
Total central axoplasmal area (mm2) 8000 1600 4800 300 5100 500 0.63
Total peripheral axoplasmal area (mm2) 12,100 1800 7100 500 7300 600 0.78
EAE: experimental autoimmune encephalomyelitis; LINGO-1: leucine-rich repeat and immunoglobulin-like domain-containing Nogo recep-
tor-interacting protein 1; mAb: monoclonal antibody; MOG-EAE: myelin oligodendrocyte glycoprotein experimental autoimmune encephalo-
myelitis; SE, standard error.
ap values for control versus anti-LINGO-1 mAb 3B5.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
6 www.sagepub.com/msjetc
 by guest on September 8, 2016mso.sagepub.comDownloaded from 
Figure 3. Histological analysis conducted on the 0.5-mm transverse sections of the pre-chiasmal optic nerve
in five regions of interest (a). Analysis indicated no significant differences in axon numbers between anti-
LINGO-1- and control-treated mice in either the peripheral (be) or the central regions (f) of the optic nerve.
Axon numbers between the two treatment conditions remained unchanged (Table 2). However, average axon
area of the central portion of the optic nerve showed a strong trend toward greater reduction in the placebo-
treated mice than the anti-LINGO-1-treated mice when compared with healthy control tissues (Table 2).
LINGO-1: leucine-rich repeat and immunoglobulin-like domain-containing Nogo receptor-interacting
protein 1.
Gresle et al.
www.sagepub.com/msjetc 7
 by guest on September 8, 2016mso.sagepub.comDownloaded from 
Normal
D
A
P
I
βI
II 
tu
bu
lin
Veh + ctrl Ab MP + ctrl Ab
Veh + 
anti-LINGO-1 mAb 
BIIB033
MP + 
anti-LINGO-1 mAb 
BIIB033
0
40
20
60
100
N
o.
 o
f a
xo
ns
/fi
el
d
80
p < 0.001
p < 0.01
Veh + ctrl Ab MP + ctrl Ab Veh + anti-LINGO-1
mAb BIIB033
MP + anti-LINGO-1
mAb BIIB033
(a)
(b)
Figure 4. LINGO-1 blockade protected the optic nerve from axonal degeneration in MOG-EAE rats. (a)
Immunohistochemical staining to visualize optic nerve axons in normal or MOG-EAE rats 28 days after the
start of the indicated antibody treatments. Scale bar ¼ 25 mm. (b) Quantification of axons from (a). Data in (b)
shown as mean  standard error of the mean (SEM). p values were determined using a one-way analysis of
variance followed by Tukey post test. Ctrl Ab: control antibody; DAPI: 4’,6-diamidino-2-phenylindole;
LINGO-1: leucine-rich repeat and immunoglobulin-like domain-containing Nogo receptor-interacting protein
1; mAb: monoclonal antibody; MOG-EAE: myelin oligodendrocyte glycoprotein experimental autoimmune
encephalomyelitis; MP: methylprednisolone; Veh: vehicle.
Figure 5. LINGO-1 is expressed in retinal ganglion cells (RGCs). Immunohistochemical staining of
LINGO-1 in the retina 14 days after optic nerve crush. Arrows indicate RGCs. Scale bar ¼ 100 mm. FG:
Fluoro-Gold; GCL: ganglion cell layer; INL: inner nuclear layer; LINGO-1: leucine-rich repeat and immu-
noglobulin-like domain-containing Nogo receptor-interacting protein 1; ONL: outer nuclear layer.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
8 www.sagepub.com/msjetc
 by guest on September 8, 2016mso.sagepub.comDownloaded from 
Figure 6. Anti-LINGO-1 monoclonal antibody (mAb) 1A7 prevented optic nerve axonal degeneration and
facilitated regeneration in a rat optic nerve crush model. (a) Images of optic nerves showing fluorescein
isothiocyanate-conjugated cholera toxin subunit B (FITC-CTB)-labeled axons proximal to the crush site in
normal or injured rats (14 days after optic nerve crush) exposed to mAb 1A7 or vehicle (veh). Arrows show
the crush site, asterisks show axonal areas. Scale bar ¼ 100 mm. (b) Images of optic nerves showing FITC-
CTB-labeled axons beyond the crush site in injured rats exposed to mAb 1A7 or veh. Arrows show axonal
outgrowth. Scale bar ¼ 100 mm. (c) Quantification of regenerating axons per section at different distances
beyond the crush sites in injured rats exposed to veh or mAb 1A7 through local or intravitreal delivery. Data
in (c) shown as mean  SEM. p values were determined using an unpaired t test. LINGO-1: leucine-rich
repeat and immunoglobulin-like domain-containing Nogo receptor-interacting protein 1.
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increased central axon atrophy was documented).
The technical challenges of en bloc mouse optic
nerve dissection and manipulation for histological
analysis also introduce variability. Larger and
longer studies with the optic nerve assessed at later
time points will be needed to fully characterize the
neuroprotective effects of LINGO-1 blockade in
mouse EAE. These studies will also determine if
Figure 7. LINGO-1 deletion enhanced optic nerve axon regeneration in a mouse optic nerve crush model.
(a) Images of optic nerves showing Alexa Fluor 488-conjugated cholera toxin subunit B-labeled axons around
the crush sites at 28 days after injury from wild-type and LINGO-1-null mice. Asterisk shows crush site. Scale
bar ¼ 500 mm. (b) Quantification of regenerating axons per section at different distances beyond the crush
site. Data in (b) shown as mean  SEM. p values were determined using an unpaired t test. LINGO-1:
leucine-rich repeat and immunoglobulin-like domain-containing Nogo receptor-interacting protein 1.
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EAE-induced axonal atrophy is a reversible phenom-
enon or indicative of irreversible damage ultimately
progressing to axonal loss.
Using an alternative model of CNS neuroinflamma-
tory disease (rat MOG-EAE), we provide additional
data to support an axonal protective effect of
LINGO-1 blockade in the optic nerve, evidenced
by increased numbers of bIII tubulin-positive axons
relative to control mice. In this experimental model,
we additionally investigated if administration of an
anti-inflammatory adjunct therapy could improve
axonal preservation following anti-LINGO-1 ther-
apy, using high-dose intravenous methylpredniso-
lone (the standard of care for humans with ON).
Although the effect of anti-LINGO-1 therapy on
axonal protection was preserved in the presence of
methylprednisolone, a synergistic or additive effect
was not observed. Furthermore, in the absence of
anti-LINGO-1 therapy, methylprednisolone was not
associated with a significant increase in bIII tubulin-
positive axon numbers, highlighting the importance
of developing therapies that are specifically targeted
to axonal injury mechanisms in acute ON to maxi-
mize patient outcomes.
Finally, we show that both local and intravitreal
administration of anti-LINGO-1 mAb 1A7 therapy
can reduce optic nerve crush-induced axonal degen-
eration and facilitated axonal outgrowth beyond the
crush site. We also confirm the deleterious role of
LINGO-1 in axonal regeneration after nerve crush
injury using LINGO-1-null mice. Hence, our studies
collectively suggest that anti-LINGO-1 therapy
could promote both axonal protection and regener-
ation in the optic nerves.
Importantly, given the supportive preclinical and
human phase I data with mAb BIIB033,8,32 a
phase II study program is ongoing. Preliminary
results from the RENEW trial (presented at the
67th Annual Meeting of the American Academy of
Neurology) showed some beneficial effect of anti-
LINGO-1 antibody therapy in cases with acute uni-
lateral ON.33 Our studies support the validity of
these observations in the human disease.
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